An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects With ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer
An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects With ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer
This study will provide pre-approval drug access to lapatinib, in combination with capecitabine, to patients whose breast cancer had progressed on other therapies
Inclusion criteria:
Exclusion criteria:
New Havey, Connecticut 06511, United States
Kalamazoo, Missouri 49007, United States
Ã…rhus C, 8000, Denmark
OYS, 90029, Finland
Pokfulam, Hong Kong
Tallaght, Dublin, 24, Ireland
Petaling Jaya Selangor, 47000, Malaysia
Newtown, Wellington, 6002, New Zealand
Sampaloc Manila, 1008, Philippines
Kyunggi-do, 410-769, South Korea
Basurto/Bilbao, 48013, Spain
Tainan County, 736, Taiwan
Cumbria, CA2 7HY, United Kingdom
Denbighshire, LL 18 5UJ, United Kingdom
Hartshill, Stoke-on-Trent, ST4 7LN, United Kingdom
Lindley, Huddersfield, HD3 3EA, United Kingdom